$輝瑞(PFE.US)$$諾和諾德(NVO.US)$$Axsome Therapeutics(AXSM.US)$$Macrogenics(MGNX.US)$ 1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly. 2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
1.$Annovis Bio(ANVS.US)$ • Ph 3 data (also Ph 2/3 in AD). • Buntanetap for Parkinson’s Disease. • Exp Jan '24 but delayed (est this qtr). 2.$Axsome Therapeutics(AXSM.US)$ • Ph 3 data (SYMPHONY). • AXS-12 for Narcolepsy. • AXS-12 has Orphan Drug Designation. 3.$G1 Therapeutics(GTHX.US)$ • Ph 3 Overall Survival (OS) data. • Trilaciclib (combo) for breast cancer (mTNBC). • DMC recommended continuation earlier in Feb. 4.$Crinetics(CRNX.US)$ • Ph 3 data (PATHFND...
The strong revenue growth mirrors the robust share price gain. Top performers like Axsome Therapeutics can continue winning for decades. This seems like a good opportunity, despite the already positive sentiment.
Despite being loss-making, Axsome Therapeutics' strong cash position and revenue increase provide a positive outlook. It's projected to improve its free cash flow with further revenue growth.
Axsome Therapeutics' 66% projected growth rate may be overly optimistic. A slower growth rate might push the break-even point further, and the high debt level of 63% of its equity amplifies the investment risk in the unprofitable company.
Pre-Market Stock Movers Gapping up $Sagimet Biosciences(SGMT.US)$ (Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.) $禮來(LLY.US)$ (The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...
Salmon Klein : 你是否在 $Macrogenics (MGNX.US)$ ?告訴我什麼時候好跳進
MangoXXXX Salmon Klein: 現在
SlowndEasyTrades Salmon Klein: 做你自己的研究,我覺得懸停在底部,買信號從模式即將開始,不要盲目跟隨我
Salmon Klein SlowndEasyTrades: 我等待到 14.8 左右,但我很忙的工作,如果它達到底部而且你在... 任何好的反饋總是非常歡迎兄弟... 只是這樣,所以謝謝
SlowndEasyTrades Salmon Klein: 當日中的雙倍底部可能不會低於 14 點,或者如果是這樣,仍有機會再進行兩個側面交易,反正我下跌了近 25%(原因保持超過頂部)